Table 3.

CD163 expression according to pathological characteristics, MSI status, and relapse in stage II colorectal cancer

	n	macCD163d	p value	n	tecCD163d	p value	n	stromaCD163d	p value
T-stage
T3	233	0.11 ± 0.21		265	0.056 ± 0.072		244	0.12 ± 0.23
T4	27	0.25 ± 0.50	NS	39	0.11 ± 0.15	< 0.05	35	0.075 ± 0.099	NS
Tumor localizationa
Colon	220	0.14 ± 0.27		262	0.062 ± 0.087		239	0.11 ± 0.23
Rectum	38	0.067 ± 0.082	NS	40	0.061 ± 0.086	NS	38	0.097 ± 0.15	NS
Tumor localization in colon
Right-sided colon	108	0.15 ± 0.30		138	0.062 ± 0.081		128	0.11 ± 0.18
Left-sided colon	112	0.13 ± 0.25	NS	124	0.063 ± 0.094	NS	111	0.11 ± 0.28	NS
Differentiationb
Well/moderate (G1–G2)	221	0.11 ± 0.23		255	0.058 ± 0.088		234	0.10 ± 0.21
Poor (G3–G4)	26	0.21 ± 0.37	NS	32	0.10 ± 0.082	< 0.01	31	0.16 ± 0.28	< 0.05
Mucinousb	13	0.27 ± 0.32	NS	17	0.050 ± 0.042	< 0.01	14	0.14 ± 0.24	NS
MSI status
MSI-H	49	0.20 ± 0.37		59	0.058 ± 0.056		57	0.13 ± 0.20
MSS/MSI-L	210	0.11 ± 0.22	0.05	238	0.063 ± 0.093	NS	215	0.10 ± 0.23	< 0.05
Relapsec
Yes	75	0.13 ± 0.26		100	0.071 ± 0.092		89	0.085 ± 0.13
No	185	0.13 ± 0.25	NS	204	0.057 ± 0.084	NS	190	0.12 ± 0.25	NS

SD standard deviation, MSI microsatellite instability, MSI-H microsatellite instability—high, MSS microsatellite—stable, MSI-L microsatellite instability—low, NS not significant, CD163 cluster of differentiation 163, macCD163 CD163 expression in tumor sample, tecCD163 CD163 expression in tumor epithelial cells, stromaCD163 CD163 expression in stroma

^aTwo tumors with localization in both the colon and rectum were excluded

^bMucinous tumors were compared with highly/moderately and poorly differentiated tumors

^cUpon exclusion of the 20 patients that received adjuvant chemotherapy, tecCD163 expression was significantly higher in the relapse group (p < 0.05)

^dValues are expressed as the mean ± SD